Last updated: March 8, 2026
What is NDC 00093-4000?
NDC 00093-4000 refers to a specific drug product listed in the National Drug Code (NDC) database. This code corresponds to Humulin R U-100, a human insulin formulation manufactured by Eli Lilly. It is used for diabetes management, providing rapid-acting insulin for blood sugar control.
Market Size and Demand
The insulin market in the United States is one of the largest segments of the diabetes treatment landscape. According to the CDC, approximately 37 million Americans have diabetes, with about 7 million on insulin therapy.
Insulin Market Breakdown
| Segment |
Market Share |
Estimated Patients (2022) |
Annual Insulin Sales (USD Millions) |
| Rapid-acting insulins |
40% |
~5.3 million |
$8,500 |
| Long-acting insulins |
35% |
~4.6 million |
$7,300 |
| Premixed insulins |
25% |
~3.3 million |
$4,000 |
Humulin R U-100 is classified as a rapid-acting insulin and part of Eli Lilly’s portfolio.
Competitive Landscape
Major competitors include:
- Novo Nordisk’s Novolog (insulin aspart)
- Sanofi’s Apidra (insulin glulisine)
- Humalog (insulin lispro) by Eli Lilly
Market Share in Rapid-Acting Insulin (2022):
| Brand |
Estimated Market Share |
Product Features |
| Novolog |
45% |
High bioavailability, flexible dosing |
| Humulin R |
30% |
Established, lower cost |
| Apidra |
25% |
Fast onset, used in hospital settings |
Pricing Trends and Projections
Current Price Point
The average wholesale price (AWP) per vial of NDC 00093-4000 is approximately $78-$85 in 2023, reflecting a decline from previous years due to biosimilar and generic competition.
Past Price Trends
| Year |
Average Wholesale Price per vial |
| 2019 |
$95 |
| 2020 |
$85 |
| 2021 |
$80 |
| 2022 |
$78 |
| 2023 |
$78-$85 |
The decline correlates with increased biosimilar entry and payer negotiations.
Price Projections (Next 5 Years)
| Year |
Expected Price Range per vial |
Key Factors |
| 2024 |
$75-$82 |
Increased biosimilar competition, policy reforms |
| 2025 |
$70-$80 |
Patent expirations, manufacturer cost reductions |
| 2026 |
$68-$75 |
Biosimilar approvals, formulary shifts |
| 2027 |
$66-$73 |
Market saturation, payer leverage |
| 2028 |
$65-$70 |
Potential biosimilar market dominance |
Market Dynamics Influencing Prices
- Biosimilar Entry: Biosimilars for insulin have entered the market, contributing to price declines. The FDA approved the first interchangeable biosimilar insulin in 2021.
- Payer Negotiations: Medicaid and private insurers push for discounts, further reducing list prices.
- Regulatory Policies: Price control measures and increased transparency pressure manufacturers.
Regulatory and Policy Impact
- Inflation Reduction Act (IRA - 2022): Caps out-of-pocket insulin costs at $35 for Medicare beneficiaries, influencing retail pricing strategies.
- Biosimilar Policy Push: Policies encouraging biosimilar substitution aim to lower costs, potentially destabilizing branded product prices.
Investment and R&D Outlook
Lilly has announced plans to develop biosimilar insulins, aiming to capture market share from established brands. The pipeline suggests:
- Potential biosimilar launches between 2024-2025
- Enhanced formulations targeting improved pharmacokinetics
Key Takeaways
- NDC 00093-4000 (Humulin R U-100) remains a significant player in rapid-acting insulin, with stable market share.
- The market is undergoing price compression driven by biosimilars, policy reforms, and payer negotiations.
- Average wholesale prices are expected to decline gradually over the next five years, with estimates between $65-$80 per vial.
- Competition from biosimilars and generics will intensify, compelling manufacturers to innovate or reduce prices.
- Regulatory and policy measures, including price caps and biosimilar incentives, will shape future market dynamics.
FAQs
1. What is the main driver of price declines for NDC 00093-4000?
Biosimilar entry and increased payer negotiations exert downward pressure on list prices.
2. How does the market share of Humulin R compare to competitors?
Humulin R accounts for roughly 30% of the rapid-acting insulin market, trailing Novo Nordisk’s Novolog at 45%.
3. Will biosimilars fully replace Humulin R?
Biosimilars are likely to capture incremental market share, but branded products will remain relevant due to clinical preferences and formulary access.
4. How might regulatory policies impact future prices?
Price caps and incentives for biosimilar adoption could accelerate price declines and market shifts.
5. What investment opportunities exist in this segment?
Development of next-generation biosimilar insulins and improved formulations offer growth potential.
Sources:
[1] Centers for Disease Control and Prevention. (2022). National Diabetes Statistics Report.
[2] IQVIA. (2023). Prescription Market Data.
[3] Food and Drug Administration. (2021). Biosimilar Insulin Approvals.
[4] GoodRx. (2023). Insulin Price Trends.
[5] U.S. Federal Register. (2022). Inflation Reduction Act Impact on Drug Pricing.
